{"id":{"repo_id":"ull","oai_identifier":"oai:riull.ull.es:915/100"},"canonical_url":"https://search.dev.ndltd.org/etd/ull/oai:riull.ull.es:915/100","repository":{"repo_id":"ull","name":"Universidad de la Laguna","base_url":"https://riull.ull.es/oai/request"},"display":{"title":"Análisis de dos esquemas de tratamiento con hierro oral e intravenoso en cirugía cardiaca : ensayo clínico en fase IV, randomizado, doble ciego y doble enmascarado","abstract":"Background: Anemia is a frequent complication after cardiopulmonary bypass surgery. Iron therapy has been variably employed by medical centres over the years. Objective: To test the clinical effectiveness of intravenous and oral iron supplementation in correcting anemia, and its impact on blood transfusion requirements, in patients undergoing cardiopulmonary bypass (CPB) surgery. Methods: A double-blind randomized placebo-controlled clinical trial with three parallel groups of patients. Group I (n=54): intravenous iron III-hydroxide sucrose complex, three doses of 100 mg /24 hours during pre- and postoperative hospitalization and 1 pill/24 h of oral placebo in the same period and during one month after discharge. Group II (n=53): oral ferrous fumarate iron 1 pill/24 hours pre- and postoperatively and during one month after discharge, and intravenous placebo while hospitalized. Group III (n=52): oral and intravenous placebo pre- and postoperatively, following the same protocol. Data were collected preoperatively, at theatre, at Intensive Care Unit admission, before hospital discharge and one month later. Results: 1) Baseline clinical and demographic characteristics and surgical procedures were similar in the three groups, 2) no inter-group differences were found in hemoglobin and hematocrit during the postoperative period, 3) the intravenous iron group showed higher serum ferritin levels at hospital discharge (1321±495 ng/mL; P<0.001) and one month later (610±387;P< 0.001) compared with the other groups, and 4) we did not observe statistical differences in blood transfusion requirements between the three groups. Conclusion: The use of intravenous or oral iron supplementation proved ineffective at correcting anemia after CPB and did not reduce blood transfusion requirements.","abstract_html":"Background: Anemia is a frequent complication after cardiopulmonary bypass surgery. Iron therapy has been variably employed by medical centres over the years. Objective: To test the clinical effectiveness of intravenous and oral iron supplementation in correcting anemia, and its impact on blood transfusion requirements, in patients undergoing cardiopulmonary bypass (CPB) surgery. Methods: A double-blind randomized placebo-controlled clinical trial with three parallel groups of patients. Group I (n=54): intravenous iron III-hydroxide sucrose complex, three doses of 100 mg /24 hours during pre- and postoperative hospitalization and 1 pill/24 h of oral placebo in the same period and during one month after discharge. Group II (n=53): oral ferrous fumarate iron 1 pill/24 hours pre- and postoperatively and during one month after discharge, and intravenous placebo while hospitalized. Group III (n=52): oral and intravenous placebo pre- and postoperatively, following the same protocol. Data were collected preoperatively, at theatre, at Intensive Care Unit admission, before hospital discharge and one month later. Results: 1) Baseline clinical and demographic characteristics and surgical procedures were similar in the three groups, 2) no inter-group differences were found in hemoglobin and hematocrit during the postoperative period, 3) the intravenous iron group showed higher serum ferritin levels at hospital discharge (1321±495 ng/mL; P&lt;0.001) and one month later (610±387;P&lt; 0.001) compared with the other groups, and 4) we did not observe statistical differences in blood transfusion requirements between the three groups. Conclusion: The use of intravenous or oral iron supplementation proved ineffective at correcting anemia after CPB and did not reduce blood transfusion requirements.","abstract_has_math":false,"creators":["Rodríguez Fortúnez, Patricia María"],"institution":"Universidad de La Laguna, Servicio de Publicaciones","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Garrido Martín, Pilar","Martínez Sanz, Rafael"],"committee_chairs":[],"committee_members":[],"year":2014,"date_issued":"2014","date_published":"2014","updated_at":"2026-08-21T16:49:21Z","subjects":[],"languages":["es"],"rights":["Licencia Creative Commons (Reconocimiento-No comercial-Sin obras derivadas 4.0 internacional)"],"rights_urls":["https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es_ES"],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["hdl:915/100"],"render_values":[{"text":"hdl:915/100","href":null,"code":true}]}]},"links":{"outbound_url":"http://riull.ull.es/xmlui/handle/915/100","outbound_label":"Repository record","outbound_source":"dc:identifier.uri"},"source_record":{"url":"https://riull.ull.es/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Ariull.ull.es%3A915%2F100","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Garrido Martín, Pilar","Martínez Sanz, Rafael"]},{"key":"dc:creator","label":"Author","values":["Rodríguez Fortúnez, Patricia María"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2014-05-13T11:18:27Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2014-05-13T11:18:27Z"]},{"key":"dc:date.issued","label":"Date","values":["2014"]},{"key":"dc:publisher","label":"Institution","values":["Universidad de La Laguna, Servicio de Publicaciones"]},{"key":"dc:type","label":"Dc Type","values":["info:eu-repo/semantics/doctoralThesis"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["es"]},{"key":"dc:rights","label":"Dc Rights","values":["Licencia Creative Commons (Reconocimiento-No comercial-Sin obras derivadas 4.0 internacional)"]},{"key":"dc:rights.uri","label":"Rights URI","values":["https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es_ES"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["hdl:915/100"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://riull.ull.es/xmlui/handle/915/100"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Background: Anemia is a frequent complication after cardiopulmonary bypass surgery. Iron therapy has been variably employed by medical centres over the years. Objective: To test the clinical effectiveness of intravenous and oral iron supplementation in correcting anemia, and its impact on blood transfusion requirements, in patients undergoing cardiopulmonary bypass (CPB) surgery. Methods: A double-blind randomized placebo-controlled clinical trial with three parallel groups of patients. Group I (n=54): intravenous iron III-hydroxide sucrose complex, three doses of 100 mg /24 hours during pre- and postoperative hospitalization and 1 pill/24 h of oral placebo in the same period and during one month after discharge. Group II (n=53): oral ferrous fumarate iron 1 pill/24 hours pre- and postoperatively and during one month after discharge, and intravenous placebo while hospitalized. Group III (n=52): oral and intravenous placebo pre- and postoperatively, following the same protocol. Data were collected preoperatively, at theatre, at Intensive Care Unit admission, before hospital discharge and one month later. Results: 1) Baseline clinical and demographic characteristics and surgical procedures were similar in the three groups, 2) no inter-group differences were found in hemoglobin and hematocrit during the postoperative period, 3) the intravenous iron group showed higher serum ferritin levels at hospital discharge (1321±495 ng/mL; P<0.001) and one month later (610±387;P< 0.001) compared with the other groups, and 4) we did not observe statistical differences in blood transfusion requirements between the three groups. Conclusion: The use of intravenous or oral iron supplementation proved ineffective at correcting anemia after CPB and did not reduce blood transfusion requirements."]},{"key":"dc:description.other","label":"Dc Description Other","values":["Background: Anemia is a frequent complication after cardiopulmonary bypass surgery. Iron therapy has been variably employed by medical centres over the years. Objective: To test the clinical effectiveness of intravenous and oral iron supplementation in correcting anemia, and its impact on blood transfusion requirements, in patients undergoing cardiopulmonary bypass (CPB) surgery. Methods: A double-blind randomized placebo-controlled clinical trial with three parallel groups of patients. Group I (n=54): intravenous iron III-hydroxide sucrose complex, three doses of 100 mg /24 hours during pre- and postoperative hospitalization and 1 pill/24 h of oral placebo in the same period and during one month after discharge. Group II (n=53): oral ferrous fumarate iron 1 pill/24 hours pre- and postoperatively and during one month after discharge, and intravenous placebo while hospitalized. Group III (n=52): oral and intravenous placebo pre- and postoperatively, following the same protocol. Data were collected preoperatively, at theatre, at Intensive Care Unit admission, before hospital discharge and one month later. Results: 1) Baseline clinical and demographic characteristics and surgical procedures were similar in the three groups, 2) no inter-group differences were found in hemoglobin and hematocrit during the postoperative period, 3) the intravenous iron group showed higher serum ferritin levels at hospital discharge (1321±495 ng/mL; P<0.001) and one month later (610±387;P< 0.001) compared with the other groups, and 4) we did not observe statistical differences in blood transfusion requirements between the three groups. Conclusion: The use of intravenous or oral iron supplementation proved ineffective at correcting anemia after CPB and did not reduce blood transfusion requirements."]},{"key":"dc:format.mimetype","label":"Dc Format Mimetype","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Análisis de dos esquemas de tratamiento con hierro oral e intravenoso en cirugía cardiaca : ensayo clínico en fase IV, randomizado, doble ciego y doble enmascarado"]}]}],"canonical_facts":{"dc:contributor.advisor":["Garrido Martín, Pilar","Martínez Sanz, Rafael"],"dc:creator":["Rodríguez Fortúnez, Patricia María"],"dc:date.accessioned":["2014-05-13T11:18:27Z"],"dc:date.available":["2014-05-13T11:18:27Z"],"dc:date.issued":["2014"],"dc:description.abstract":["Background: Anemia is a frequent complication after cardiopulmonary bypass surgery. Iron therapy has been variably employed by medical centres over the years. Objective: To test the clinical effectiveness of intravenous and oral iron supplementation in correcting anemia, and its impact on blood transfusion requirements, in patients undergoing cardiopulmonary bypass (CPB) surgery. Methods: A double-blind randomized placebo-controlled clinical trial with three parallel groups of patients. Group I (n=54): intravenous iron III-hydroxide sucrose complex, three doses of 100 mg /24 hours during pre- and postoperative hospitalization and 1 pill/24 h of oral placebo in the same period and during one month after discharge. Group II (n=53): oral ferrous fumarate iron 1 pill/24 hours pre- and postoperatively and during one month after discharge, and intravenous placebo while hospitalized. Group III (n=52): oral and intravenous placebo pre- and postoperatively, following the same protocol. Data were collected preoperatively, at theatre, at Intensive Care Unit admission, before hospital discharge and one month later. Results: 1) Baseline clinical and demographic characteristics and surgical procedures were similar in the three groups, 2) no inter-group differences were found in hemoglobin and hematocrit during the postoperative period, 3) the intravenous iron group showed higher serum ferritin levels at hospital discharge (1321±495 ng/mL; P<0.001) and one month later (610±387;P< 0.001) compared with the other groups, and 4) we did not observe statistical differences in blood transfusion requirements between the three groups. Conclusion: The use of intravenous or oral iron supplementation proved ineffective at correcting anemia after CPB and did not reduce blood transfusion requirements."],"dc:description.other":["Background: Anemia is a frequent complication after cardiopulmonary bypass surgery. Iron therapy has been variably employed by medical centres over the years. Objective: To test the clinical effectiveness of intravenous and oral iron supplementation in correcting anemia, and its impact on blood transfusion requirements, in patients undergoing cardiopulmonary bypass (CPB) surgery. Methods: A double-blind randomized placebo-controlled clinical trial with three parallel groups of patients. Group I (n=54): intravenous iron III-hydroxide sucrose complex, three doses of 100 mg /24 hours during pre- and postoperative hospitalization and 1 pill/24 h of oral placebo in the same period and during one month after discharge. Group II (n=53): oral ferrous fumarate iron 1 pill/24 hours pre- and postoperatively and during one month after discharge, and intravenous placebo while hospitalized. Group III (n=52): oral and intravenous placebo pre- and postoperatively, following the same protocol. Data were collected preoperatively, at theatre, at Intensive Care Unit admission, before hospital discharge and one month later. Results: 1) Baseline clinical and demographic characteristics and surgical procedures were similar in the three groups, 2) no inter-group differences were found in hemoglobin and hematocrit during the postoperative period, 3) the intravenous iron group showed higher serum ferritin levels at hospital discharge (1321±495 ng/mL; P<0.001) and one month later (610±387;P< 0.001) compared with the other groups, and 4) we did not observe statistical differences in blood transfusion requirements between the three groups. Conclusion: The use of intravenous or oral iron supplementation proved ineffective at correcting anemia after CPB and did not reduce blood transfusion requirements."],"dc:format.mimetype":["application/pdf"],"dc:identifier":["hdl:915/100"],"dc:identifier.uri":["http://riull.ull.es/xmlui/handle/915/100"],"dc:language.iso":["es"],"dc:publisher":["Universidad de La Laguna, Servicio de Publicaciones"],"dc:rights":["Licencia Creative Commons (Reconocimiento-No comercial-Sin obras derivadas 4.0 internacional)"],"dc:rights.uri":["https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es_ES"],"dc:title":["Análisis de dos esquemas de tratamiento con hierro oral e intravenoso en cirugía cardiaca : ensayo clínico en fase IV, randomizado, doble ciego y doble enmascarado"],"dc:type":["info:eu-repo/semantics/doctoralThesis"]},"updated_at":"2026-08-21T16:49:21Z"}